Crystalline Forms of an RSK Inhibitor
Summary
The EPO published patent application EP3924352A1 by Phoenix Molecular Designs covering crystalline forms of RSK (Ribosomal S6 Kinase) inhibitors used in cancer treatment. The application was published on April 1, 2026 and designates 36 European member states. The patent grants enforceable intellectual property rights over the specific solid-state forms of the therapeutic compound.
What changed
The EPO published patent application EP3924352A1 on April 1, 2026, covering crystalline forms of RSK inhibitors filed by Phoenix Molecular Designs. The application names five inventors and claims priority related to pharmaceutical compositions. Designated states include all major European patent office member states.
Pharmaceutical and biotech companies developing kinase inhibitor therapies should monitor this publication for potential freedom-to-operate implications. Generic and biosimilar developers in the oncology space may need to evaluate whether their compounds fall within the scope of these crystal form claims when assessing market entry strategies.
What to do next
- Monitor patent landscape for kinase inhibitor developments
- Assess freedom to operate if developing competing RSK inhibitors
- Review potential licensing opportunities
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CRYSTALLINE FORMS OF AN RSK INHIBITOR
Publication EP3924352A1 Kind: A1 Apr 01, 2026
Applicants
Phoenix Molecular Designs
Inventors
WINNIKE, Richard, MCPHERSON, Elaine, FLAHIVE, Erik, DUNN, Sandra, E., LOUGHREY, Jonathan
IPC Classifications
C07D 471/14 20060101AFI20221011BHEP A61K 31/4985 20060101ALI20221011BHEP A61P 35/00 20060101ALI20221011BHEP C12N 9/12 20060101ALI20221011BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.